Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares

MPM BioVentures 2018, L.P., a 10% stakeholder and director of Entrada Therapeutics, Inc., announced the sale of approximately $1.91 million worth of the company's common shares in early September 2026. The transactions took place in three separate occurrences, with the stock trading at $7.11 per share, down 31% year-to-date but up 36% over the past year.

On September 4, 2026, affiliated entities sold 38,500 shares at prices ranging from $7.01 to $7.16, with a weighted average sale price of $7.11. On September 8, 2026, another 192,500 shares were sold at prices between $6.97 and $7.70, averaging $7.41. The final sale occurred on September 9, 2026, with 28,837 shares exchanged at prices between $7.02 and $7.54, at an average of $7.13.

In total, these sales generated $1,905,767. Analysts view Entrada Therapeutics as undervalued, with price targets ranging from $11 to $25, and the stock listed among opportunities on a most undervalued stocks list. Messrs. Evnin, Foley, and Gadicke, managing directors of the general partners and managers of the affiliated entities, disclosed their indirect ownership of 3,885,115 shares following these transactions.